MA27813A1 - Preparation pharmaceutique topique - Google Patents

Preparation pharmaceutique topique

Info

Publication number
MA27813A1
MA27813A1 MA27912A MA27912A MA27813A1 MA 27813 A1 MA27813 A1 MA 27813A1 MA 27912 A MA27912 A MA 27912A MA 27912 A MA27912 A MA 27912A MA 27813 A1 MA27813 A1 MA 27813A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparation
topical pharmaceutical
administering
inhibitor
observed
Prior art date
Application number
MA27912A
Other languages
English (en)
Inventor
Christina Bolle
Rudolf Linder
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of MA27813A1 publication Critical patent/MA27813A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F41B5/123—Compound crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/14—Details of bows; Accessories for arc shooting
    • F41B5/1442—Accessories for arc or bow shooting
    • F41B5/1469—Bow-string drawing or releasing devices

Abstract

L'invention a trait à une préparation pharmaceutique topique permettant d'administrer un inhibiteur PDE 4 à peine soluble. Une biodisponibilité systémique étonnamment bonne est manifestée lors de l'exécution de cette forme de dosage.
MA27912A 2002-05-28 2004-10-21 Preparation pharmaceutique topique MA27813A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10223828 2002-05-28
EP02011830 2002-05-28
DE10311613 2003-03-14

Publications (1)

Publication Number Publication Date
MA27813A1 true MA27813A1 (fr) 2006-04-03

Family

ID=29587313

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27912A MA27813A1 (fr) 2002-05-28 2004-10-21 Preparation pharmaceutique topique

Country Status (33)

Country Link
US (7) US20060084685A1 (fr)
EP (3) EP2020243B1 (fr)
JP (3) JP5652983B2 (fr)
KR (2) KR20050014844A (fr)
CN (3) CN1655823B (fr)
AT (2) ATE417628T1 (fr)
AU (2) AU2003232828B2 (fr)
BR (2) BR0311337A (fr)
CA (2) CA2486917C (fr)
CY (2) CY1110312T1 (fr)
DE (2) DE60334692D1 (fr)
DK (3) DK1511481T3 (fr)
EA (2) EA010416B1 (fr)
ES (3) ES2693094T3 (fr)
HK (2) HK1079437A1 (fr)
HR (1) HRP20041211B1 (fr)
HU (1) HUE039709T2 (fr)
IL (3) IL164935A (fr)
IS (1) IS2639B (fr)
LT (1) LT2020243T (fr)
MA (1) MA27813A1 (fr)
ME (1) ME00565A (fr)
MX (2) MXPA04011612A (fr)
NO (2) NO334882B1 (fr)
NZ (3) NZ537308A (fr)
PL (3) PL211870B1 (fr)
PT (3) PT1511481E (fr)
RS (1) RS51104B (fr)
SI (2) SI1511516T1 (fr)
TR (1) TR201815573T4 (fr)
UA (2) UA81910C2 (fr)
WO (2) WO2003099334A1 (fr)
ZA (2) ZA200408649B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EP2020243B1 (fr) * 2002-05-28 2018-08-15 AstraZeneca AB Préparation pharmaceutique applicable de manière topique
MXPA05003063A (es) 2002-09-20 2005-05-27 Alcon Inc Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos.
FR2851247B1 (fr) * 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
SI1606261T1 (sl) 2003-03-10 2010-03-31 Nycomed Gmbh Novi postopek za pripravo roflumilasta
WO2005067892A1 (fr) * 2004-01-10 2005-07-28 Biolipid, Inc. Compositions lipidiques et methodes d'utilisation
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
NZ560269A (en) * 2005-03-08 2010-12-24 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
JP5383183B2 (ja) * 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
WO2006132342A1 (fr) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. Gouttes oculaires contenant du roflumilast
MX2008010774A (es) 2006-02-21 2008-09-01 Eisai R&D Man Co Ltd Derivados de 4-(3-benzoilaminofenil)-6, 7-dimetoxi-2-metilaminoqui nazolina.
AU2008215411B2 (en) 2007-02-16 2012-11-22 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
EP2202229B1 (fr) 2007-08-17 2012-03-14 Eisai R&D Management Co., Ltd. Nouvelle préparation pour une utilisation externe
ATE538102T1 (de) 2007-08-17 2012-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung eines chinazolinderivats
JP6071554B2 (ja) 2009-10-30 2017-02-01 ネステク ソシエテ アノニム イヌ科動物の眼の健康を維持するため、及び眼の病気を改善するための方法
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
ES2408132B1 (es) * 2010-09-08 2014-04-04 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento de la epífora.
EP3320902B1 (fr) 2011-03-07 2021-02-17 Amgen (Europe) GmbH Procédés de traitement de maladies à l'aide de composés isoindolines
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
US20140296301A1 (en) * 2011-06-28 2014-10-02 Bayer Pharma Aktiengesellschaft Topical ophthalmological pharmaceutical composition containing regoragenib
US9951335B2 (en) * 2012-04-10 2018-04-24 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD
WO2014012954A1 (fr) 2012-07-18 2014-01-23 Takeda Gmbh Traitement de l'asthme sévère partiellement régulé ou non régulé
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
EP2916868B1 (fr) 2012-11-08 2022-05-11 Rhizen Pharmaceuticals S.A. Compositions pharmaceutiques contenant un inhibiteur de pde4 et un inhibiteur de pi3 kinase delta ou un double inhibiteur de pi3 kinase delta et gamma
CA2921308A1 (fr) 2013-08-16 2015-02-19 Universiteit Maastricht Traitement d'une deficience cognitive a l'aide d'un inhibiteur de pde4
CN105434328A (zh) * 2014-09-01 2016-03-30 天津药物研究院有限公司 一种含罗氟司特固体分散体的固体制剂及其制备方法
WO2016063906A1 (fr) * 2014-10-24 2016-04-28 久光製薬株式会社 Promédicament
CN104997959A (zh) * 2015-08-21 2015-10-28 蔡宇平 一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) * 2016-07-11 2019-10-01 赵晨 一种遗传性Usher综合征的致病突变及其检测试剂
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
CA3102689C (fr) * 2018-06-04 2023-08-29 Arcutis, Inc. Methode et formulation pour ameliorer le temps de latence de penetration de la peau du roflumilast
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
US20200155524A1 (en) * 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
WO2021155173A1 (fr) 2020-01-31 2021-08-05 Arcutis Biotherapeutics, Inc. Formulation de roflumilast topique ayant une administration et une demi-vie plasmatique améliorées
BR112022007459A2 (pt) * 2020-05-07 2022-11-29 Arcutis Biotherapeutics Inc Método para tratar uma barreira epidérmica com função diminuída, composição farmacêutica, composição e método para reduzir a extração de lipídios epidérmicos e aumentar a função de barreira epidérmica
WO2022169615A1 (fr) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Formulations de roflumilast à profil pharmacocinétique amélioré
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
AU2022218993A1 (en) * 2021-02-10 2023-08-03 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
KR20240039092A (ko) * 2021-06-01 2024-03-26 아이디어 바이오, 엘엘씨 안구 약물을 위한 연장 방출 약물 전달 시스템 및 사용 방법
CA3231766A1 (fr) * 2021-09-22 2023-03-30 Elizabeth W. JEFFORDS Methodes de traitement de maladies inflammatoires oculaires
WO2024058848A1 (fr) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Compositions pharmaceutiques de roflumilast et de solvants capables de dissoudre des quantités élevées de médicament

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
DK0706513T3 (da) * 1993-07-02 2002-09-09 Altana Pharma Ag Fluoralkoxysubstituerede benzamider og anvendelse deraf som cyklisk-nukleotid phosphodiesteraseinhibitorer
CN1128955A (zh) * 1993-08-10 1996-08-14 藤泽药品工业株式会社 经皮吸收制剂
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
CA2345362A1 (fr) * 1998-09-29 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Nouveaux sels d'un compose de pyridopyrazine et cristaux desdits sels
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
DE60015098T2 (de) 1999-03-10 2006-02-02 Altana Pharma Ag 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AU772909B2 (en) * 1999-10-29 2004-05-13 Smithkline Beecham Corporation Method for administering a phosphodiesterase 4 inhibitor
OA12170A (en) * 2000-01-31 2006-05-08 Pfizer Prod Inc Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes.
JP2004502643A (ja) * 2000-02-16 2004-01-29 ユニバーシティ・オブ・ネブラスカ・メディカル・センター 線維症性疾患の治療法および治療用組成物
JP2003534328A (ja) * 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
US6528527B2 (en) * 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) * 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
EP2020243B1 (fr) * 2002-05-28 2018-08-15 AstraZeneca AB Préparation pharmaceutique applicable de manière topique

Also Published As

Publication number Publication date
EP1511516A1 (fr) 2005-03-09
EP1511516B1 (fr) 2008-12-17
JP5652983B2 (ja) 2015-01-14
ATE485821T1 (de) 2010-11-15
CY1121133T1 (el) 2019-12-11
DK2020243T3 (en) 2018-11-19
AU2003240719A1 (en) 2003-12-12
CN101491520B (zh) 2011-03-16
IL165065A0 (en) 2005-12-18
NZ553731A (en) 2007-07-27
BR0311339A (pt) 2005-03-22
JP2005529928A (ja) 2005-10-06
CN100490804C (zh) 2009-05-27
CA2486910C (fr) 2011-11-29
IL164935A (en) 2010-12-30
JP5683538B2 (ja) 2015-03-11
US20080280958A1 (en) 2008-11-13
US20060084685A1 (en) 2006-04-20
US20190029956A1 (en) 2019-01-31
CN101491520A (zh) 2009-07-29
DE60325354D1 (de) 2009-01-29
UA88523C2 (ru) 2009-10-26
BR0311337A (pt) 2005-03-15
JP2005529930A (ja) 2005-10-06
DE60334692D1 (de) 2010-12-09
MXPA04011612A (es) 2005-03-07
US20140303215A1 (en) 2014-10-09
ES2354971T3 (es) 2011-03-21
NO334916B1 (no) 2014-07-14
JP2012229245A (ja) 2012-11-22
CA2486917A1 (fr) 2003-12-04
EP1511481B1 (fr) 2010-10-27
HRP20041211B1 (hr) 2013-06-30
PL211870B1 (pl) 2012-07-31
DK1511516T3 (da) 2009-04-06
EA020569B1 (ru) 2014-12-30
RS101404A (en) 2007-02-05
AU2003232828B2 (en) 2010-06-24
TR201815573T4 (tr) 2018-11-21
ES2319517T3 (es) 2009-05-08
PL372095A1 (en) 2005-07-11
RS51104B (sr) 2010-10-31
IS2639B (is) 2010-06-15
SI1511516T1 (sl) 2009-06-30
WO2003099334A1 (fr) 2003-12-04
ME00565A (en) 2011-12-20
HK1079437A1 (en) 2006-04-07
PL372082A1 (en) 2005-07-11
EA200702588A1 (ru) 2008-08-29
PL397021A1 (pl) 2012-03-26
HK1079445A1 (en) 2006-04-07
MXPA04011528A (es) 2005-02-14
IS7612A (is) 2004-12-23
UA81910C2 (uk) 2008-02-25
ES2693094T3 (es) 2018-12-07
CA2486917C (fr) 2011-11-22
HUE039709T2 (hu) 2019-01-28
ZA200408649B (en) 2007-12-27
DK1511481T3 (da) 2011-01-24
LT2020243T (lt) 2018-11-12
PT2020243T (pt) 2018-11-09
EP2020243A1 (fr) 2009-02-04
CN1655823A (zh) 2005-08-17
EA200401517A1 (ru) 2005-06-30
AU2003232828A1 (en) 2003-12-12
ATE417628T1 (de) 2009-01-15
PL212134B1 (pl) 2012-08-31
KR20110122230A (ko) 2011-11-09
IL164935A0 (en) 2005-12-18
NZ537308A (en) 2009-09-25
US20110313005A1 (en) 2011-12-22
EA010416B1 (ru) 2008-08-29
EP2020243B1 (fr) 2018-08-15
NZ536920A (en) 2007-04-27
NO20045506L (no) 2004-12-16
PT1511516E (pt) 2009-02-20
SI2020243T1 (sl) 2018-11-30
US20060084684A1 (en) 2006-04-20
US20210116207A1 (en) 2021-04-22
KR20050014844A (ko) 2005-02-07
EP1511481A1 (fr) 2005-03-09
CA2486910A1 (fr) 2003-12-04
AU2003240719B2 (en) 2009-12-10
KR101307093B1 (ko) 2013-09-11
ZA200409584B (en) 2006-05-31
IL209657A0 (en) 2011-02-28
PT1511481E (pt) 2011-01-14
HRP20041211A2 (hr) 2006-04-30
CN1655823B (zh) 2010-05-26
NO20045656L (no) 2004-12-27
CY1110312T1 (el) 2015-01-14
WO2003099278A1 (fr) 2003-12-04
IL165065A (en) 2010-11-30
NO334882B1 (no) 2014-06-30
CN1655782A (zh) 2005-08-17

Similar Documents

Publication Publication Date Title
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
NO20032510D0 (no) Organiske forbindelser
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
ATE337016T1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
SE0102440D0 (sv) New compound